First synthesised in 1929, it primarily occurs as a white-off white powder that is either ingested or snorted, although intravenous abuse has also been described; it is believed to induce the release of monoamines and inhibit their reuptake, similarly to the amfetamines. Its chief effects include: euphoria, increased energy, feelings of empathy, increased libido, sweating, high heart rate, headache, hyperactivity, features of excitement, pupil dilation, talkativeness, rashes, cold blue fingers or toes, psychosis, increased libido, seizures, feeling hot and teeth grinding. After these effects wear off people often experience symptoms characteristic of the stimulant come-down syndrome such as: lethargy and low mood. It is believed to mediate its effects by inhibiting the reuptake of monoamine neurotransmitters and inducing their release. It is generally said to be less empathogenic than MDMA and to be more stimulant like the amfetamines. Ingestion usually takes at least 45 minutes to produce effects whereas snorting it and injecting it generally produces near-immediate effects.
- ChemSpider entry
- Independent Scientific Committee on Drugs entry
- PubChem entry
- Wikipedia good article on mephedrone
- ↑ Dargan, PI; Sedefov, R; Gallegos, A; Wood, DM (July-August 2011). "The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone).". Drug Testing and Analysis 3 (7-8): 454–63. doi:10.1002/dta.312. PMID 21755604.
- ↑ Schifano, F; Albanese, A; Fergus, S; Stair, JL; Deluca, P; Corazza, O; Davey, Z; Corkery, J; Siemann, H; Scherbaum, N; Farre', M; Torrens, M; Demetrovics, Z; Ghodse, AH; Psychonaut Web, Mapping; ReDNet Research, Groups (April 2011). "Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.". Psychopharmacology 214 (3): 593–602. doi:10.1007/s00213-010-2070-x. PMID 21072502.
- ↑ Winstock, AR; Marsden, J; Mitcheson, L (March 2010). "What should be done about mephedrone?". BMJ 340: c1605. doi:10.1136/bmj.c1605. PMID 20332508.